Treatment Options for Acne Rosacea



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2009 Sep 1;80(5):461-468.

  Patient information: See related handout on acne rosacea, written by the authors of this article.

Rosacea is a common chronic, and sometimes progressive, dermatosis. It is characterized, alone or in combination, by central facial erythema, symmetric flushing, stinging sensation, inflammatory lesions (papules and pustules), telangiectasias, and phymatous changes (tissue hyperplasia and nodules). Rosacea can occur in adults of any ethnicity, and adversely affects patients' quality of life. The condition can be effectively controlled with therapy tailored to the specific subtype of rosacea that is affecting the patient. Topical metronidazole, sulfacetamide/sulfur, and azelaic acid are generally effective for patients with mild rosacea. For moderate papulopustular rosacea, combination therapy with oral tetracyclines and topical agents is the first-line choice. Treatment with a topical agent, such as metronidazole, may help maintain remission. Patients with ocular involvement may benefit from long-term oral antibiotics and metronidazole gel. Referral to a subspecialist is necessary for patients who have ocular rosacea with ophthalmic complications, severe or recalcitrant rosacea, or phymatous changes.

Rosacea is a common skin condition with characteristic symptoms and signs, including symmetric flushing, stinging sensation, inflammatory lesions (papules and pustules), and telangiectasias on the face. It may also cause inflammation of the eyes and eyelids. In most patients, the central area of the face is affected, such as the nose, forehead, chin, and perioral areas. Phymatous changes include thickened skin and large pores. Clinical findings represent a spectrum of disease with one or several predominating characteristics, including a pattern of exacerbations and relative inactivity. The National Rosacea Society classifies rosacea into four subtypes: erythematotelangiectatic, papulopustular, phymatous, and ocular. These subtypes are further classified by severity based on the number of papules/pustules and plaques (Figures 1 through 4).1

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating References

Drug therapy should be based on rosacea classification, severity, and response to previous treatment regimens.

C

6

The following may be recommended to reduce rosacea flares:

C

9, 10

• Use of emollient, noncomedogenic moisturizers and mild, fragrance-free, soap-free cleansers that have a nonalkaline or neutral pH level

• Use of broad-spectrum sunscreen containing either zinc oxide or titanium dioxide, and wide-brimmed hats

• Avoidance of astringents and other skin care products containing alcohol, menthol, eucalyptus oil, clove oil, peppermint, witch hazel, or sodium lauryl sulfate

Dermatologic laser therapy may be considered for background erythema and telangiectasia.

C

12, 13

Initial drug therapy for mild rosacea should include appropriate topical regimens, such as antibiotics, immunomodulators, or retinoids. First-line topical regimens (e.g., metronidazole [Metrogel], azelaic acid [Azelex], sulfacetamide/sulfur) should be applied once or twice daily.

A

5, 1416

Initial therapy for moderate to severe rosacea should include oral treatment or a combination of topical and oral treatments. First-line oral medications include tetracycline, doxycycline, and minocycline (Minocin). Subantimicrobial dosing should be considered.

B

5, 20, 2226

Subantimicrobial dose, once-daily doxycycline (alone or added to metronidazole therapy) may reduce inflammatory lesions.

B

20, 22

Mild ocular rosacea should be treated with eyelid hygiene (e.g., hot compresses, eyelid cleansing) and topical agents.

C

5, 32

Moderate ocular rosacea should be treated with oral drug therapy (tetracycline class).

C

5, 32


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.xml.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

View Table

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating References

Drug therapy should be based on rosacea classification, severity, and response to previous treatment regimens.

C

6

The following may be recommended to reduce rosacea flares:

C

9, 10

• Use of emollient, noncomedogenic moisturizers and mild, fragrance-free, soap-free cleansers that have a nonalkaline or neutral pH level

• Use of broad-spectrum sunscreen containing either zinc oxide or titanium dioxide, and wide-brimmed hats

• Avoidance of astringents and other skin care products containing alcohol, menthol, eucalyptus oil, clove oil, peppermint, witch hazel, or sodium lauryl sulfate

Dermatologic laser therapy may be considered for background erythema and telangiectasia.

C

12, 13

Initial drug therapy for mild rosacea should include appropriate topical regimens, such as antibiotics, immunomodulators, or retinoids. First-line topical regimens (e.g., metronidazole [Metrogel], azelaic acid [Azelex], sulfacetamide/sulfur) should be applied once or twice daily.

A

5, 1416

Initial therapy for moderate to severe rosacea should include oral treatment or a combination of topical and oral treatments. First-line oral medications include tetracycline, doxycycline, and minocycline (Minocin). Subantimicrobial dosing should be considered.

B

5, 20, 2226

Subantimicrobial dose, once-daily doxycycline (alone or added to metronidazole therapy) may reduce inflammatory lesions.

B

20, 22

Mild ocular rosacea should be treated with eyelid hygiene (e.g., hot compresses, eyelid cleansing) and topical agents.

C

5, 32

Moderate ocular rosacea should be treated with oral drug therapy (tetracycline class).

C

5, 32


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.xml.

Figure 1.

Erythematotelangiectatic rosacea (subtype 1). (A) Mild. (B) Moderate. (C) Severe.

Figures reprinted with permission from Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46(4):584–587.

View Large


Figure 1.

Erythematotelangiectatic rosacea (subtype 1). (A) Mild. (B) Moderate. (C) Severe.

Figures reprinted with permission from Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46(4):584–587.


Figure 1.

Erythematotelangiectatic rosacea (subtype 1). (A) Mild. (B) Moderate. (C) Severe.

Figures reprinted with permission from Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46(4):584–587.

Figure 2.

Papulopustular rosacea (subtype 2). (A) Mild. (B) Moderate. (C) Severe.

Figures reprinted with permission from Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46(4):584–587.

View Large


Figure 2.

Papulopustular rosacea (subtype 2). (A) Mild. (B) Moderate. (C) Severe.

Figures reprinted with permission from Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46(4):584–587.


Figure 2.

Papulopustular rosacea (subtype 2). (A) Mild. (B) Moderate. (C) Severe.

Figures reprinted with permission from Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46(4):584–587.

Figure 3.

Phymatous rosacea (subtype 3). (A) Mild. (B) Moderate. (C) Severe.

Figures reprinted with permission from Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46(4):584–587.

View Large


Figure 3.

Phymatous rosacea (subtype 3). (A) Mild. (B) Moderate. (C) Severe.

Figures reprinted with permission from Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46(4):584–587.


Figure 3.

Phymatous rosacea (subtype 3). (A) Mild. (B) Moderate. (C) Severe.

Figures reprinted with permission from Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46(4):584–587.

Figure 4.

Ocular rosacea (subtype 4). (A) Mild. (B) Moderate. (C) Severe.

Figures reprinted with permission from Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46(4):584–587.

View Large


Figure 4.

Ocular rosacea (subtype 4). (A) Mild. (B) Moderate. (C) Severe.

Figures reprinted with permission from Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46(4):584–587.


Figure 4.

Ocular rosacea (subtype 4). (A) Mild. (B) Moderate. (C) Severe.

Figures reprinted with permission from Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46(4):584–587.

Rosacea affects an estimated 14 million patients in the United States.2 It is more common in white persons but can occur in persons of other ethnicities. Rosacea is somewhat more likely to occur in women. It generally emerges when patients are in their 30s, although it can develop in younger age groups.2 The influence of heredity on the development of rosacea has not been well studied. However, one survey suggests that first- and second-degree relatives of patients with rosacea have a higher rate of rosacea, and persons of Irish, English, or German ancestry are more likely to develop the disease.3 Although this evidence is weak, it supports epidemiologic patterns that are anecdotally noted in the literature.

The differential diagnosis of rosacea includes acne vulgaris, systemic lupus erythematosus, polymyositis, sarcoidosis, photodermatitis, drug eruptions (particularly from iodides and bromides), granulomas of the skin, and perioral dermatitis. The differential diagnosis of ocular rosacea may include staphylococcal and seborrheic blepharokeratoconjunctivitis, and sebaceous gland carcinoma.4

A 2005 Cochrane review concluded that the quality of studies evaluating rosacea treatments is generally poor.5  Drug therapy is based on rosacea classification, severity, and response to previous treatment regimens (Table 1).1,6,7 Figure 5 presents a treatment algorithm for rosacea.

Table 1.

Classification of Rosacea and Treatment by Subtypes

Subtype Clinical features Comments

Erythematotelangiectatic (subtype 1)

Persistent erythema of the central face

Most difficult subtype to treat

Prolonged flushing

Topical therapy may be irritating to sensitive skin

Telangiectasias often present

Burning or stinging possible (especially with topical agents)

Ocular rosacea may coexist

Papulopustular (subtype 2)

Persistent central erythema with small papules and pinpoint pustules

Easiest subtype to treat

Burning, stinging, or flushing is possible

Sparing of the periocular and sometimes perioral areas

May resemble acne vulgaris, without comedones

May include episodes of facial edema

Phymatous (subtype 3)

Marked skin thickening and irregular nodularities of nose, chin, ears, forehead, or eyelids

More common in men

Rhinophyma

Ocular (subtype 4)

Watery, bloodshot eyes

Affects nearly 60 percent of patients with rosacea

Dry eye, foreign body sensation, irritation, photophobia

Often undiagnosed

Blepharitis, conjunctivitis, eyelid irregularities, inflammation

Corneal complications may decrease visual acuity; vision loss possible


note: See Figure 5 for a treatment algorithm based on rosacea subtypes.

Information from references 1, 6, and 7.

Table 1.   Classification of Rosacea and Treatment by Subtypes

View Table

Table 1.

Classification of Rosacea and Treatment by Subtypes

Subtype Clinical features Comments

Erythematotelangiectatic (subtype 1)

Persistent erythema of the central face

Most difficult subtype to treat

Prolonged flushing

Topical therapy may be irritating to sensitive skin

Telangiectasias often present

Burning or stinging possible (especially with topical agents)

Ocular rosacea may coexist

Papulopustular (subtype 2)

Persistent central erythema with small papules and pinpoint pustules

Easiest subtype to treat

Burning, stinging, or flushing is possible

Sparing of the periocular and sometimes perioral areas

May resemble acne vulgaris, without comedones

May include episodes of facial edema

Phymatous (subtype 3)

Marked skin thickening and irregular nodularities of nose, chin, ears, forehead, or eyelids

More common in men

Rhinophyma

Ocular (subtype 4)

Watery, bloodshot eyes

Affects nearly 60 percent of patients with rosacea

Dry eye, foreign body sensation, irritation, photophobia

Often undiagnosed

Blepharitis, conjunctivitis, eyelid irregularities, inflammation

Corneal complications may decrease visual acuity; vision loss possible


note: See Figure 5 for a treatment algorithm based on rosacea subtypes.

Information from references 1, 6, and 7.

Treatment of Rosacea Subtypes

Figure 5.

Treatment algorithm for rosacea subtypes.

View Large

Treatment of Rosacea Subtypes


Figure 5.

Treatment algorithm for rosacea subtypes.

Treatment of Rosacea Subtypes


Figure 5.

Treatment algorithm for rosacea subtypes.

Nonpharmacologic Therapy

The initial therapeutic approach for rosacea, especially the erythematotelangiectatic and papulopustular subtypes, is avoidance of known triggers or exacerbating factors (Table 28) when possible. These factors may be specific to individual patients.

Patients with rosacea should avoid sun exposure, wear wide-brimmed hats when outdoors, and use a broad-spectrum sunscreen daily that has a sun protection factor of at least 15. Because sunscreen products can be irritating, patients with rosacea may better tolerate formulations with a simethicone or dimethicone base that contain titanium dioxide or zinc oxide.9,10 Astringents and other skin care products containing alcohol, menthol, eucalyptus oil, clove oil, peppermint, witch hazel, or sodium lauryl sulfate should be avoided. Emollient, noncomedogenic moisturizers and fragrance-free, soap-free products with a nonalkaline or neutral pH level are recommended.10,11

Although few studies have examined nonpharmacologic treatments for erythematotelangiectatic and phymatous rosacea, vascular lasers are the mainstay of nonpharmacologic therapy and have been useful for treating resistant telangiectasias, persistent erythema, and recalcitrant rosacea.12,13 Cosmetic improvement of rhinophyma may be achieved with mechanical dermabrasion, carbon-dioxide laser peel, cold steel excision, electrosurgery, and surgical shave techniques; however, the evidence for the effectiveness of these treatments is limited.

Table 2.

Common Trigger Factors for Rosacea

Trigger factor Percentage of patients affected*

Sun exposure

81

Emotional stress

79

Hot weather

75

Wind

57

Strenuous exercise

56

Alcohol consumption

52

Hot baths

51

Cold weather

46

Spicy foods

45

Humidity

44

Certain skin-care products

41

Indoor heat

41

Hot beverages

36

Certain cosmetics

27

Medications

15

Other factors

24


*— Based on a survey of 1,066 patients with rosacea.

Adapted with permission from National Rosacea Society. Rosacea triggers survey. http://www.rosacea.org/patients/materials/triggersgraph.php. Accessed May 14, 2009.

Table 2.   Common Trigger Factors for Rosacea

View Table

Table 2.

Common Trigger Factors for Rosacea

Trigger factor Percentage of patients affected*

Sun exposure

81

Emotional stress

79

Hot weather

75

Wind

57

Strenuous exercise

56

Alcohol consumption

52

Hot baths

51

Cold weather

46

Spicy foods

45

Humidity

44

Certain skin-care products

41

Indoor heat

41

Hot beverages

36

Certain cosmetics

27

Medications

15

Other factors

24


*— Based on a survey of 1,066 patients with rosacea.

Adapted with permission from National Rosacea Society. Rosacea triggers survey. http://www.rosacea.org/patients/materials/triggersgraph.php. Accessed May 14, 2009.

Topical Therapy

Topical regimens are first-line therapies for mild papulopustular rosacea because there is less risk of adverse events, drug interactions, and antibiotic resistance. The severity of the patient's presentation helps guide the decision to initiate topical therapy alone or in combination with systemic therapy. Systemic therapy should be withdrawn when adequate response occurs. Topical therapies for rosacea are summarized in Table 3.

Table 3.

Topical Therapies for Rosacea

Therapy Mechanism of action Dosage Symptoms improved Cost of generic (brand)* In retail discount programs

Metronidazole

Antibiotic, anti-inflammatory

0.75% or 1%; once or twice per day

Erythema, pustules, nodules

0.75%: $50 to $60 ($214) for 45 g

1%: NA ($137 to $160) for 60 g

Azelaic acid

Antibiotic, anti-inflammatory

15%; once or twice per day

Erythema, pustules, nodules

NA ($127) for 50 g

Sulfacetamide/sulfur

Antibacterial, keratolytic

10%/5%; once or twice per day

Erythema, pustules, nodules

$29 for 50 g ($66 to $131 for 45 g)

Benzoyl peroxide

Antibacterial

5%; once or twice per day

Erythema, pustules, nodules

$13 ($22) for 45 g

Erythromycin

Antibiotic, anti-inflammatory

2%; twice per day

Pustules, nodules

$19 for 30 g ($33 for 27 g)

Clindamycin

Antibiotic, anti-inflammatory

1%; twice per day

Pustules, nodules

$18 ($63) for 30 g

Silymarin and methylsulfonylmethane

Bioflavonoid, anti-inflammatory, photoprotective

Twice per day

Erythema, telangiectasias, nodules, stinging

Tretinoin

Epidermal keratinization

0.025%, 0.05%, or 0.1%; at bedtime

Pustules, nodules

0.025%: $40 ($57 to $77) for 20 g

0.05%: $46 ($88) for 20 g

0.1%: $47 ($101) for 20 g

Adapalene

Epidermal keratinization

0.1% or 0.3%; at bedtime

Pustules, nodules

0.1%: NA ($169 to $172) for 45 g

0.3%: NA ($161) for 45 g

Permethrin

Antiparasitic (Demodex folliculorum)

5%; twice per day

Erythema, pustules, nodules

$20 ($19 to $73) for 60 g


note: Therapies are listed in order of preference and effectiveness.

NA = not available.

*— Estimated retail price of one month's treatment based on information obtained at http://www.drugstore.com (accessed June 1, 2009). Generic price listed first; brand price listed in parentheses.

†—May be available at discounted prices ($10 or less for one month's treatment) at one or more national retail chains.

Table 3.   Topical Therapies for Rosacea

View Table

Table 3.

Topical Therapies for Rosacea

Therapy Mechanism of action Dosage Symptoms improved Cost of generic (brand)* In retail discount programs

Metronidazole

Antibiotic, anti-inflammatory

0.75% or 1%; once or twice per day

Erythema, pustules, nodules

0.75%: $50 to $60 ($214) for 45 g

1%: NA ($137 to $160) for 60 g

Azelaic acid

Antibiotic, anti-inflammatory

15%; once or twice per day

Erythema, pustules, nodules

NA ($127) for 50 g

Sulfacetamide/sulfur

Antibacterial, keratolytic

10%/5%; once or twice per day

Erythema, pustules, nodules

$29 for 50 g ($66 to $131 for 45 g)

Benzoyl peroxide

Antibacterial

5%; once or twice per day

Erythema, pustules, nodules

$13 ($22) for 45 g

Erythromycin

Antibiotic, anti-inflammatory

2%; twice per day

Pustules, nodules

$19 for 30 g ($33 for 27 g)

Clindamycin

Antibiotic, anti-inflammatory

1%; twice per day

Pustules, nodules

$18 ($63) for 30 g

Silymarin and methylsulfonylmethane

Bioflavonoid, anti-inflammatory, photoprotective

Twice per day

Erythema, telangiectasias, nodules, stinging

Tretinoin

Epidermal keratinization

0.025%, 0.05%, or 0.1%; at bedtime

Pustules, nodules

0.025%: $40 ($57 to $77) for 20 g

0.05%: $46 ($88) for 20 g

0.1%: $47 ($101) for 20 g

Adapalene

Epidermal keratinization

0.1% or 0.3%; at bedtime

Pustules, nodules

0.1%: NA ($169 to $172) for 45 g

0.3%: NA ($161) for 45 g

Permethrin

Antiparasitic (Demodex folliculorum)

5%; twice per day

Erythema, pustules, nodules

$20 ($19 to $73) for 60 g


note: Therapies are listed in order of preference and effectiveness.

NA = not available.

*— Estimated retail price of one month's treatment based on information obtained at http://www.drugstore.com (accessed June 1, 2009). Generic price listed first; brand price listed in parentheses.

†—May be available at discounted prices ($10 or less for one month's treatment) at one or more national retail chains.

EFFECTIVE TOPICAL THERAPY

Metronidazole. Metronidazole (Metrogel) is one of two topical medications approved by the U.S. Food and Drug Administration (FDA) for the treatment of rosacea. Its effectiveness is based on several valid, well-controlled trials.5 Different preparations of metronidazole have been compared with placebo and active comparators, with outcomes ranging from papule/pustule counts and erythema ratings to physician global rosacea scores and patient opinion scores.5 Topical metronidazole is generally well tolerated with few local skin adverse reactions, and it is the recommended topical therapy for rosacea.

Azelaic Acid. The effectiveness and safety of the acne drug azelaic acid (Azelex) has been supported by two double-blind, randomized controlled trials (RCTs), leading the FDA to approve its use for the treatment of rosacea.5 Two RCTs comparing azelaic acid with metronidazole over 12 to 15 weeks concluded that azelaic acid is comparable to or exceeds the clinical effectiveness of metronidazole in treating erythema, nodules, papules, and pustules.5 Azelaic acid is not effective for telangiectasias. Adverse events were insignificant. Azelaic acid may be used as a first- or second-line therapy for rosacea.

Other Effective Topical Treatments. Three studies have investigated the effectiveness of sulfacetamide/sulfur cream. One study compared the cream with placebo,5 and two compared it with metronidazole.14,15 Although weak in quality, these studies appear to support the use of sulfacetamide/sulfur cream as an alternative to topical metronidazole. Limited data suggest that benzoyl peroxide/clindamycin (Benzaclin) and benzoyl peroxide/erythromycin (Benzamycin) gels are effective for the treatment of inflammatory rosacea.5 Two RCTs showed statistically and clinically significant improvement with these gels.5 Adverse events included burning and itching at the treatment site, which are common with the use of benzoyl peroxide.

TOPICAL THERAPIES WITH LIMITED OR UNKNOWN EFFECTIVENESS

Adapalene (Differin), a retinoic acid receptor agonist used for treating acne vulgaris, has been shown to effectively reduce papules and pustules, but not erythema or telangiectasias.16 Silymarin, a bioflavonoid with anti-inflammatory activity, is combined with methylsulfonylmethane for its photoprotective attributes. Studies have shown that silymarin combined with methylsulfonylmethane improves papules, erythema, hydration, and itching, but not pustule number, making it an option for patients with erythematotelangiectatic rosacea.17 When used twice daily with sunscreen, the antiparasitic agent permethrin has been shown to effectively reduce papules and erythema, but not telangiectasias, pustules, and rhinophyma.5 Evidence for these topical agents requires further validation in larger well-controlled studies before they can be recommended for treating rosacea.

Systemic Therapy

Evidence for using oral antibiotics to treat rosacea is limited and is often based on clinical experience or older, low-quality studies instead of on well-designed RCTs. Initial therapy for moderate to severe rosacea should include oral treatment or a combination of topical and oral treatments. Because rosacea is a chronic disease, the long-term use of antibiotics can lead to adverse effects. Additionally, concerns about long-term use of antibiotics leading to resistant bacterial strains need to be addressed. One potential management strategy is to taper the dosage of oral antibiotics after six to 12 weeks of successful treatment, transitioning to topical agents only.1820  Systemic therapies for rosacea are summarized in Table 4. Licorice is the only herbal therapy studied in clinical trials that reduced erythema in patients with mild to moderate rosacea.21

Table 4.

Systemic Therapies for Rosacea

Therapy* Dosage Adverse effects Cost of generic (brand) In retail discount programs

Doxycycline

40 (subantimicrobial dose therapy) to 100 mg once or twice per day for six to 12 weeks

GI upset, allergic reactions, photosensitivity

40 mg: NA ($236) 100 mg: $20 ($70)

Drug interactions: antacids, anticoagulants

Contraindicated in pregnant and lactating women

Tetracycline

250 to 500 mg twice per day for six to 12 weeks; intermittent, low-dose therapy when indicated

GI upset, candida, photosensitivity

$15 (NA)

Drug interactions: antacids, anticoagulants

Contraindicated in pregnant and lactating women

Minocycline (Minocin)

50 to 100 mg twice per day or sustained-action formula once per day for six to 12 weeks

GI upset, allergic reactions, vertigo, photosensitivity

$32 ($273)

Drug interactions: antacids, anticoagulants

Contraindicated in pregnant and lactating women

Metronidazole (Flagyl)

250 mg once per day for four to six weeks

Disulfiram-like reaction possible, headache

$34 ($189)

Rare neuropathy, seizures

Drug interactions: lithium, anticoagulants, phenytoin (Dilantin)

Azithromycin

500 mg on day 1, followed by 250 mg daily for four days

GI upset, candida, cholestasis

$99 ($312)

Drug interactions: erythromycin

Isotretinoin (Accutane)

0.5 to 1 mg per kg, divided, twice per day for 10 to 60 days (only for severely recalcitrant nodular rosacea)

Teratogenicity, hypercholesterolemia, hypertriglyceridemia, musculoskeletal changes, hepatotoxicity, decreased night vision, mood changes (e.g., depression)

NA ($350)

Drug interactions: vitamin A supplements


note: Therapies are listed in order of preference and effectiveness.

GI = gastrointestinal; NA = not available.

*— Anti-inflammatory, bacteriostatic medications. Pustules and nodules are improved with these medications.

†—Estimated retail price of one month's treatment based on information obtained at http://www.drugstore.com (accessed June 1, 2009). Generic price listed first; brand price listed in parentheses.

‡—May be available at discounted prices ($10 or less for one month's treatment) at one or more national retail chains.

Table 4.   Systemic Therapies for Rosacea

View Table

Table 4.

Systemic Therapies for Rosacea

Therapy* Dosage Adverse effects Cost of generic (brand) In retail discount programs

Doxycycline

40 (subantimicrobial dose therapy) to 100 mg once or twice per day for six to 12 weeks

GI upset, allergic reactions, photosensitivity

40 mg: NA ($236) 100 mg: $20 ($70)

Drug interactions: antacids, anticoagulants

Contraindicated in pregnant and lactating women

Tetracycline

250 to 500 mg twice per day for six to 12 weeks; intermittent, low-dose therapy when indicated

GI upset, candida, photosensitivity

$15 (NA)

Drug interactions: antacids, anticoagulants

Contraindicated in pregnant and lactating women

Minocycline (Minocin)

50 to 100 mg twice per day or sustained-action formula once per day for six to 12 weeks

GI upset, allergic reactions, vertigo, photosensitivity

$32 ($273)

Drug interactions: antacids, anticoagulants

Contraindicated in pregnant and lactating women

Metronidazole (Flagyl)

250 mg once per day for four to six weeks

Disulfiram-like reaction possible, headache

$34 ($189)

Rare neuropathy, seizures

Drug interactions: lithium, anticoagulants, phenytoin (Dilantin)

Azithromycin

500 mg on day 1, followed by 250 mg daily for four days

GI upset, candida, cholestasis

$99 ($312)

Drug interactions: erythromycin

Isotretinoin (Accutane)

0.5 to 1 mg per kg, divided, twice per day for 10 to 60 days (only for severely recalcitrant nodular rosacea)

Teratogenicity, hypercholesterolemia, hypertriglyceridemia, musculoskeletal changes, hepatotoxicity, decreased night vision, mood changes (e.g., depression)

NA ($350)

Drug interactions: vitamin A supplements


note: Therapies are listed in order of preference and effectiveness.

GI = gastrointestinal; NA = not available.

*— Anti-inflammatory, bacteriostatic medications. Pustules and nodules are improved with these medications.

†—Estimated retail price of one month's treatment based on information obtained at http://www.drugstore.com (accessed June 1, 2009). Generic price listed first; brand price listed in parentheses.

‡—May be available at discounted prices ($10 or less for one month's treatment) at one or more national retail chains.

EFFECTIVE ORAL AGENTS

Tetracyclines. Subantimicrobial dose antibiotics may act as anti-inflammatory agents without creating bacterial resistance.18 Oral tetracyclines, most commonly doxycycline, tetracycline, and minocycline (Minocin), have been used to treat papulopustular rosacea for more than four decades. Doxycycline is the only drug approved by the FDA to specifically treat papulopustular rosacea. Two RCTs with a total of 269 patients have shown that subantimicrobial dose doxycycline, alone or added to topical metronidazole therapy, reduces inflammatory lesions in patients with moderate to severe rosacea.22

Three to four weeks of therapy with a tetracycline is required before substantial improvement occurs; typical duration of therapy ranges from six to 12 weeks. Three small, older studies evaluating the use of tetracycline in 181 patients with rosacea concluded that tetracycline is significantly more effective than placebo, but specific outcomes were not included.5 In one study, after tetracycline therapy was terminated, relapse rates within one and six months were 24 and 60 percent, respectively.23 Four years after termination of therapy, 31 percent of patients remained in remission.

Second-Generation Macrolides. Second-generation clarithromycin and azithromycin have been studied in patients with rosacea, but study quality is poor. Azithromycin demonstrated a 75 percent (P <.001) decrease in total symptom scores, including erythema, telangiectasias, papules, pustules, edema, and scaling. Azithromycin (500 mg three times per week) appeared to be as effective as doxycycline (100 mg daily) in decreasing facial lesions in two unblinded trials of 118 total patients.2426

Metronidazole. In two studies with a total of 69 patients, oral metronidazole (Flagyl) was as effective as oral tetracycline in reducing papules and pustules; however, study quality was poor.5,27 Oral metronidazole is a problematic option for patients with rosacea because of rare adverse effects (e.g., neuropathy, seizures) and its disulfiram-like properties.

Isotretinoin. Isotretinoin (Accutane) has been reported to be effective for treating rosacea, including rhinophyma, and appears to positively affect more than one subtype of the disease.28,29 One small RCT, including 22 patients with moderate rosacea, showed that low-dose oral isotretinoin and topical tretinoin 0.025% cream (Retin-A) both significantly reduced erythema, papules, and telangiectasias by the ninth week of treatment; combining the medications had no additional benefit.28 It is unknown whether isotretinoin can lead to permanent remission of rosacea. In patients with rhinophyma, the size and number of sebaceous glands have decreased with oral isotretinoin.29 Isotretinoin is the least studied of oral agents, and appropriate dosing and optimal duration of treatment have not been determined. Isotretinoin may be an alternative therapy, especially in men and in women beyond childbearing. Although this treatment does not cause antibiotic resistance, vigilance is required because of adverse effects.

ORAL AGENTS COMPARED WITH TOPICAL TREATMENT

In one RCT, topical clindamycin lotion (Cleocin) was shown to be a safe alternative to oral tetracycline and appeared to be superior in eradicating pustules.5 One study comparing oral tetracycline (250 mg twice per day) with metronidazole 1% cream showed no difference in lesion counts or erythema; however, the number of lesions appeared to begin decreasing more quickly with tetracycline.5

Ocular Rosacea

Nearly 60 percent of persons with rosacea have ocular involvement. Symptoms include foreign body sensation, photophobia, lid margin telangiectasia, meibomian gland inflammation and inspissation, marginal corneal ulcers, and vascularization.30 Ocular involvement may antedate skin involvement. In one study, 20 percent of patients with rosacea presented with ocular symptoms before skin lesions, 53 percent presented with skin lesions before ocular symptoms, and 27 percent had simultaneous onset of ocular and skin findings.31 Ocular rosacea typically has a chronic waxing and waning course.

Mild ocular rosacea usually responds well to topical agents and eyelid hygiene. A small blinded RCT demonstrated that eyelid hygiene using metronidazole 0.75% gel and the application of warm compresses twice per day helped to significantly improve eyelid scores after 12 weeks.5 Moderate ocular rosacea should be treated with oral therapy. In one small randomized, non–placebo-controlled trial, oral tetracycline and doxycycline appeared to equally control the symptoms of ocular rosacea; however, the outcome in this study was physician opinion.32 In one older RCT, signs and symptoms of ocular rosacea improved in 65 percent of the 35 patients taking oral oxytetracycline (no longer available in the United States) compared with 28 percent of the 35 patients taking placebo; however, no statistical results were given.5

The Authors

CONSTANCE GOLDGAR, MS, PA-C, is an assistant professor in the Department of Family and Preventive Medicine at the University of Utah, Salt Lake City, and is associate director of the university's Physician Assistant Program.

DAVID J. KEAHEY, MSPH, PA-C, is associate director of graduate studies in the University of Utah Physician Assistant Program.

JOHN HOUCHINS, MD, is an assistant professor in the Department of Family and Preventive Medicine at the University of Utah and is medical director of the university's Physician Assistant Program.

Address correspondence to Constance Goldgar, MS, PA-C, University of Utah Physician Assistant Program, 375 Chipeta Way, Suite A, Salt Lake City, UT 84115 (e-mail: cgoldgar@upap.utah.edu). Reprints are not available from the authors.

Author disclosure: Nothing to disclose.

REFERENCES

1. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46(4):584–587.

2. Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller A, Leffell DJ. Fitzpatrick's Dermatology in General Medicine. 7th ed. NewYork, NY:McGraw Hill; 2007.

3. National Rosacea Society. Rosacea review. http://www.rosacea.org/rr/2008/spring/article_3.php. Accessed July 18, 2008.

4. Randleman JB, Loft ES, Song CD. Ocular rosacea. http://emedicine.medscape.com/article/1197341-overview. (subscription required). Accessed May 26, 2009.

5. van Zuuren EJ, Graber MA, Hollis S, Chaudhry M, Gupta AK, Gover M. Interventions for rosacea Cochrane Database Syst Rev. 2005;(3):CD003262.

6. Powell FC. Clinical practice. Rosacea. N Engl J Med. 2005;352(8):793–803.

7. Smith SB, Smith JB. Rosacea. PIER. American College of Physicians, 2009. http://pier.acponline.org/physicians/diseases/d614/d614.html (subscription required). Accessed May 21, 2009.

8. National Rosacea Society. Rosacea triggers survey. http://www.rosacea.org/patients/materials/triggersgraph.php. Accessed May 14, 2009.

9. Katz HI, Fraser J. Lifestyle changes to manage sun exposure and other rosacea tripwires. Skin & Aging. 2003;11(10):S12–S16.

10. Del Rosso JQ. Adjunctive skin care in the management of rosacea: cleansers, moisturizers, and photoprotectants. Cutis. 2005;75(3 suppl):17–21.

11. Blount BW, Pelletier AL. Rosacea: a common, yet commonly overlooked, condition. Am Fam Physician. 2002;66(3):435–440.

12. Lonne-Rahm S, Nordlind K, Edström DW, Ros AM, Berg M. Laser treatment of rosacea: a pathoetiological study. Arch Dermatol. 2004;140(11):1345–1349.

13. Bernstein EF, Kligman A. Rosacea treatment using the new-generation, high-energy, 595 nm, long pulse-duration pulsed-dye laser. Lasers Surg Med. 2008;40(4):233–239.

14. Lebwohl MG, Medansky RS. The comparative efficacy of sodium sulfacetamide 10% sulfur 5% lotion and metronidazole 0.75% in the treatment of rosacea. J Geriatr Dermatol. 1995;3:183–185.

15. Torok HM, Webster G, Dunlap FE, Egan N, Jarratt M, Stewart D. Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea. Cutis. 2005;75(6):357–363.

16. Altinyazar HC, Koca R, Tekin NS, Estürk E. Adapalene vs. metronidazole gel for the treatment of rosacea. Int J Dermatol. 2005;44(3):252–255.

17. Berardesca E, Cameli N, Cavallotti C, Levy JL, Piérard GE, de Paoli Ambrosi G. Combined effects of silymarin and methylsulfonylmethane in the management of rosacea: clinical and instrumental evaluation. J Cosmet Dermatol. 2008;7(1):8–14.

18. Leyden JJ, Del Rosso JQ, Webster GF. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. Cutis. 2007;79(6 suppl):9–25.

19. Skidmore R, Kovach R, Walker C, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol. 2003;139(4):459–464.

20. Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56(5):791–802.

21. Rigopoulos D, Kalogeromitros D, Gregoriou S, et al. Randomized placebo-controlled trial of a flavonoid-rich plant extract-based cream in the treatment of rosacea. J Eur Acad Dermatol Venereol. 2005;19(5):564–568.

22. Sanchez J, Somolinos AL, Almodóvar PI, Webster G, Bradshaw M, Powala C. A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. J Am Acad Dermatol. 2005;53(5):791–797.

23. Knight AG, Vickers CF. A follow-up of tetracycline-treated rosacea. With special reference to rosacea keratitis. Br J Dermatol. 1975;93(5):577–580.

24. Bakar O, Demirçay Z, Gürbüz O. Therapeutic potential of azithromycin in rosacea. Int J Dermatol. 2004;43(2):151–154.

25. Akhyani M, Ehsani AH, Ghiasi M, Jafari AK. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial. Int J Dermatol. 2008;47(3):284–288.

26. Kus S, Yucelten D, Aytug A. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of acne vulgaris. Clin Exp Dermatol. 2005;30(3):215–220.

27. Nasir MA. Treatment of rosacea with tetracycline and metronidazole—a comparative study. J Pak Med Assoc. 1985;35(5):148–149.

28. Ertl GA, Levine N, Kligman AM. A comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea. Arch Dermatol. 1994;130(3):319–324.

29. Jansen T, Plewig G. Clinical and histological variants of rhinophyma, including nonsurgical treatment modalities. Facial Plast Surg. 1998;14(4):241–253.

30. Kligman AM. Ocular rosacea. Current concepts and therapy. Arch Dermatol. 1997;133(1):89–90.

31. Borrie P. Rosacea with special reference to its ocular manifestations. Br J Dermatol. 1953;65(12):458–463.

32. Frucht-Pery J, Sagi E, Hemo I, Ever-Hadani P. Efficacy of doxycycline and tetracycline in ocular rosacea. Am J Ophthalmol. 1993;116(1):88–92.

This is one in a series of “Clinical Pharmacology” articles coordinated by Allen F. Shaughnessy, PharmD, Tufts University Family Medicine Residency at Cambridge Health Alliance, Malden, Mass.



Copyright © 2009 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Download PDF
  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in AFP

More in Pubmed

Navigate this Article